Navigation Links
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
Date:8/6/2009

ce unplanned cash requirements, and may not received additional anticipated payments under its collaborations, any of which could shorten the estimated period in which Curis will have cash to fund its operations and which could also adversely affect Curis' estimated operating expenses for 2009 and beyond. - Curis faces risks relating to its ability to enter into and maintain planned collaborations for development candidates under its targeted cancer programs, its ability to maintain its current collaborations with Genentech and Debiopharm, and the risk that any such collaborators will not perform adequately. - Curis also faces other risk factors identified in its Annual Report on Form 10-K for the year ended December 31, 2008, its Quarterly Report for the Quarter ended June 30, 2009 and other filings that it periodically makes with the Securities and Exchange Commission.

In addition, any forward-looking statements represent the views only as of today and should not be relied upon as representing Curis' views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.

    Debiopharm S.A. Contacts
    Dr Jean-Maurice Dumont
    Director, Search & Evaluation
    Department
    jmdumont@debiopharm.com

    Maurice Wagner
    Director Corporate Affairs &
    Communication mwagner@debiopharm.com
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69

    Additional Media Contacts

    In London

    Maitland
    Brian Hudspith
    Tel: +44(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York

    Russo Partners, LLC
    
'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
2. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Japanese Cancer Association and Debiopharm Honour Japanese Research
6. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
7. Debiopharm and EPFL Establish an Oncology Chair
8. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
9. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , FREISING-WEIHENSTEPHAN, Germany , ... preclinical data for its proprietary PRS-110 Anticalin(R),compound, which targets ... in a xenograft mouse model. The results provide an,indication ... may,be of significant therapeutic value in treating cancer. A ...
... ... supplies irrigation management solutions. The company was approved for $250,000 for completion and commercialization ... plant is the sensor™.” , ... (Vocus) April 30, 2010 -- Smartfield, Inc. is ...
... DENVER , April 29 HEALTHeCAREERS Network , ... and career resources. , , ...   http://www.newscom.com/cgi-bin/prnh/20100204/FL49504LOGO-a ) , , ... The Society for Cardiovascular Angiography and Interventions (SCAI) recently joined the Network, ...
Cached Biology Technology:Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program 2$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2Healthcare Web site Expands Reach to Cardiology Professionals 2Healthcare Web site Expands Reach to Cardiology Professionals 3
(Date:4/17/2014)... professor Rajendra Singh Thursday as a "Champion of ... solar deployment in the residential, commercial and industrial ... of Electrical and Computer Engineering and director of ... local hero leading the charge across the country ... power and driving policy changes at the local ...
(Date:4/17/2014)... novel method to help kidney stone sufferers ensure ... possible., Kidney stones represent a major medical problem ... untreated, apart from being particularly painful, they can ... many patients treated successfully, stone recurrence is also ... to diagnosis and treatment needs to be identified ...
(Date:4/17/2014)... University researchers have detected new early-warning signs of the ... could have far-reaching implications for the diagnosis and treatment ... 25 million Americans. , "We had not expected to ... early stages," said Ann Elsner, professor and associate dean ... of the study. "We set out to study the ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Dangerous disease often spreads faster than it takes to ... at Kansas State University have developed a test to ... Sanjeev Narayanan, assistant professor, and Greg Peterson, research microbiologist, ... use a device called a DNA spotted microarray to ...
... double-stranded DNA into the space of a typical chromosome, ... genetic material it contains. "It is like compacting ... Professor Emeritus in Physics at the University of Chicago. ... is showing that these and related organisms may have ...
... D.C. (August 21, 2008) The Aplastic Anemia ... patients that the U.S. Food & Drug Administration (FDA) ... data from the AZA-001 trial, which found that Vidaza ... (myelodysplastic syndromes) patients. Vidaza was also shown to delay ...
Cached Biology News:Rapid test for pathogens developed by K-State researchers 2Exploding chromosomes fuel research about evolution of genetic storage 2Exploding chromosomes fuel research about evolution of genetic storage 3
... This kit allows for quick and reproducible immunoprecipitation ... The system is more reproducible than regular IPs, ... protein A/G agarose without disrupting the agarose bed. ... and Release is reversible, and elution of the ...
... Polyclonal Antibody, Unconjugated ... a dilution of 1/100. IP: Use ... Use at an assay dependent dilution. ... tested in other applications. Optimal ...
Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Using multicolor analysis in a modern flow ... cells that are differentially labeled with fluorescent ... dyes typically used for cell labeling are ... by a flow cytometers filters. Thus, the ...
Biology Products: